DICP OpenIR
学科主题分析化学
Metabolic biomarker discovery and confirmation by using metabonomics
Xu GW(许国旺); Chen J(陈静); Zhao XJ(赵欣捷); Yin PY(尹沛源); Lu X(路鑫); Kong HW(孔宏伟)
会议文集Metabolomics 2011
会议名称7th International Conference of the Metabolomics Society
会议日期2011-6-27
2011
会议地点凯恩斯
页码1-0
出版者待补充
出版地待补充
合作性质分会特邀报告
部门归属1808
主办者Metabolomics Society
英文摘要Metabonomics is a part of systems biology, it has shown the great potential of finding biomarker group for disease diagnosis. Generally, NMR or chromatography-mass spectrometry is used to analyze as many metabolites with the molecular weights smaller than 1,000 daltons as possible. Multi-variable data analysis methods are used to classify different groups, and define the significantly changed metabolites to produce new biomarkers. Unfortunately, at this moment, many studies are only in the discovery stage, the confirmation with large scaled samples is very poor, leading to the over-use of the word ‘biomarker’. In this lecture we shall report a two-stage metabonomics method. In the discovery step the typical samples are selected to define the differential metabolites by using the non-target LC-MS metabolic profiling analysis. In the confirmation step, large amount of samples with different clinical backgrounds are investigated by using the target analysis based on MRM monitoring to test the usefulness of the above differential metabolites, further define the potential biomarkers. The liver cancer and ovarian cancer will be taken as the examples to show our method. It will be seen the confirmation is a very necessary step, the poor specificity is a main disadvantage for the metabolic markers in the discovery stage, many differential metabolites are found to be influenced by different life styles or other diseases.; Metabonomics is a part of systems biology, it has shown the great potential of finding biomarker group for disease diagnosis. Generally, NMR or chromatography-mass spectrometry is used to analyze as many metabolites with the molecular weights smaller than 1,000 daltons as possible. Multi-variable data analysis methods are used to classify different groups, and define the significantly changed metabolites to produce new biomarkers. Unfortunately, at this moment, many studies are only in the discovery stage, the confirmation with large scaled samples is very poor, leading to the over-use of the word ‘biomarker’. In this lecture we shall report a two-stage metabonomics method. In the discovery step the typical samples are selected to define the differential metabolites by using the non-target LC-MS metabolic profiling analysis. In the confirmation step, large amount of samples with different clinical backgrounds are investigated by using the target analysis based on MRM monitoring to test the usefulness of the above differential metabolites, further define the potential biomarkers. The liver cancer and ovarian cancer will be taken as the examples to show our method. It will be seen the confirmation is a very necessary step, the poor specificity is a main disadvantage for the metabolic markers in the discovery stage, many differential metabolites are found to be influenced by different life styles or other diseases.
文献类型会议论文
条目标识符http://cas-ir.dicp.ac.cn/handle/321008/116052
专题中国科学院大连化学物理研究所
通讯作者Xu GW(许国旺)
推荐引用方式
GB/T 7714
Xu GW,Chen J,Zhao XJ,et al. Metabolic biomarker discovery and confirmation by using metabonomics[C]. 待补充:待补充,2011:1-0.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[许国旺]的文章
[陈静]的文章
[赵欣捷]的文章
百度学术
百度学术中相似的文章
[许国旺]的文章
[陈静]的文章
[赵欣捷]的文章
必应学术
必应学术中相似的文章
[许国旺]的文章
[陈静]的文章
[赵欣捷]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。